Breakthrough CAR-T Therapy for Acute Myeloid Leukemia Advances as Second Patient Treated

CMS Proposes Pay Bump for CAR-T in FY 2026

The Centers for Medicare & Medicaid Services (CMS) proposed to continue using its Medicare Severity Diagnosis-Related Group (MS-DRG) for chimeric antigen receptor T-cell (CAR-T) treatment stays in fiscal year (FY) 2026, but with a 17% increase in the base rate. CMS also proposed to continue providing differential reimbursement based on whether a drug was provided as part of a clinical trial, with a parallel increase proposed. The financial impac…

Hemogenyx Pharma Plc (LON:HEMO) Second Patient Treated with HG-CT-1 CAR-T Therapy

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company’s ongoing Phase I clinical trial of HG-CT-1, itsRead More...

Breakthrough CAR-T Therapy for Acute Myeloid Leukemia Advances as Second Patient Treated

New milestone in Phase I trial for resistant leukemia therapy shows promising safety profile. HG-CT-1 advances toward potential treatment for adults with R/R AML. See trial data.